ArticleProceedings of the National Academy of Sciences of the United States of America2024
In-patient evolution of a high-persister
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Contributions of persisters and the Eagle effect to survival ofMicrobiology spectrum · 2026Article
- Association ofPathogens (Basel, Switzerland) · 2026Article
- Loss of O-antigen due toScience advances · 2026Article
- Heterogeneity in microbial antibiotic responses: genetic basis and within-host evolution.Trends in genetics : TIG · 2026Review
- Beyond metabolic dormancy: metabolic rewiring in bacterial persistence.Nature communications · 2026Review
- Identification of a novel gene inAntimicrobial agents and chemotherapy · 2026Article
- Article
- Geographic containment and virulence-resistance trade-offs drive the evolution of hypervirulentiMeta · 2025Article
- Article
- Conservation and divergence of ciprofloxacin persister survival mechanisms between Pseudomonas aeruginosa and Escherichia coli.PLoS genetics · 2025Article
- Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coli in recurrent and multi-site infections.Gut pathogens · 2025Article
- Article
- Evolution of Resistant Mutants inMicroorganisms · 2025Article
- Article
- Mechanistic insights and therapeutic innovations in engineered nanomaterial-driven disruption of biofilm dynamics.RSC advances · 2025Review
- Lactate promotes invasive Klebsiella pneumoniae liver abscess syndrome by increasing capsular polysaccharide biosynthesis via the PTS-CRP axis.Nature communications · 2025Article
- Disruption of sulfur transferase complex increases bacterial intramacrophage persistence.PLoS pathogens · 2025Article
- UNRAVELING CRP/cAMP-MEDIATED METABOLIC REGULATION INbioRxiv : the preprint server for biology · 2025Article
- Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery.npj antimicrobials and resistance · 2025Article
- Broad-spectrum tolerance to disinfectant-mediated bacterial killing due to mutation of the PheS aminoacyl tRNA synthetase.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Gram-negative bacterial bloodstream infections (GNB-BSI) are common and frequently lethal. Despite appropriate antibiotic treatment, relapse of GNB-BSI with the same bacterial strain is common and associated with poor clinical outcomes and high healthcare costs. The role of persister cells, which are sub-populations of bacteria that survive for prolonged periods in the presence of bactericidal antibiotics, in relapse of GNB-BSI is unclear. Using a cohort of patients with relapsed GNB-BSI, we aimed to determine how the pathogen evolves within the patient between the initial and subsequent episodes of GNB-BSI and how these changes impact persistence. Using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.